Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-cash Items (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Non-cash Items for 16 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items fell 25.13% to $3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Dec 2025, down 25.13% year-over-year, with the annual reading at $3.4 million for FY2025, 25.13% down from the prior year.
  • Non-cash Items hit $3.4 million in Q4 2025 for Ironwood Pharmaceuticals, down from $4.5 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $5.8 million in Q4 2022 to a low of $2.9 million in Q4 2023.
  • Historically, Non-cash Items has averaged $4.2 million across 5 years, with a median of $4.5 million in 2021.
  • Biggest five-year swings in Non-cash Items: crashed 49.53% in 2023 and later surged 55.49% in 2024.
  • Year by year, Non-cash Items stood at $4.5 million in 2021, then grew by 27.78% to $5.8 million in 2022, then crashed by 49.53% to $2.9 million in 2023, then soared by 55.49% to $4.5 million in 2024, then dropped by 25.13% to $3.4 million in 2025.
  • Business Quant data shows Non-cash Items for IRWD at $3.4 million in Q4 2025, $4.5 million in Q4 2024, and $2.9 million in Q4 2023.